Heart Failure With Preserved Ejection Fraction and Di

Journal of the American College of Cardiology 73, 602-611 DOI: 10.1016/j.jacc.2018.11.033

Citation Report

#	Article	IF	CITATIONS
1	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. International Journal of Molecular Sciences, 2019, 20, 3264.	4.1	93
2	Left Ventricular Diastolic Dysfunction in Type 2 Diabetes—Progress and Perspectives. Diagnostics, 2019, 9, 121.	2.6	21
3	Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical Studies. Journal of Clinical Medicine, 2019, 8, 792.	2.4	32
4	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diabetes and Vascular Disease Research, 2019, 16, 399-414.	2.0	26
5	Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart. Cardiovascular Drugs and Therapy, 2020, 34, 823-834.	2.6	9
6	Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes. Circulation, 2020, 142, 1246-1248.	1.6	0
7	Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. European Journal of Preventive Cardiology, 2020, 27, 27-34.	1.8	38
8	Advances in Exosomes Derived from Different Cell Sources and Cardiovascular Diseases. BioMed Research International, 2020, 2020, 1-11.	1.9	8
9	Osteopontin and LDLR Are Upregulated in Hearts of Sudden Cardiac Death Victims With Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus. Frontiers in Cardiovascular Medicine, 2020, 7, 610282.	2.4	3
10	Ellagic Acid as a Tool to Limit the Diabetes Burden: Updated Evidence. Antioxidants, 2020, 9, 1226.	5.1	40
11	Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovascular Diabetology, 2020, 19, 55.	6.8	27
12	Negative synergism of diabetes mellitus and obesity in patients with heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study. International Journal of Cardiovascular Imaging, 2020, 36, 2027-2038.	1.5	12
13	Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction. Heart Failure Reviews, 2022, 27, 219-234.	3.9	2
14	Longitudinal Changes in Cardiac Structure and Function From Adolescence to Young Adulthood in Participants With Type 2 Diabetes Mellitus. Circulation: Heart Failure, 2020, 13, e006685.	3.9	21
15	Distinct cardiac energy metabolism and oxidative stress adaptations between obese and non-obese type 2 diabetes mellitus. Theranostics, 2020, 10, 2675-2695.	10.0	37
16	Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE. Cardiovascular Diabetology, 2020, 19, 106.	6.8	10
17	Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction. Heart Rhythm, 2020, 17, 1025-1033.	0.7	34
18	Editor-in-Chief's Top Picks From 2019. Journal of the American College of Cardiology, 2020, 75, 776-834.	2.8	0

ARTICLE IF CITATIONS # Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 19 3.114 diabetes. ESC Heart Failure, 2020, 7, 1168-1177. Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction. Cardiovascular Research, 3.8 28 2021, 117, 1325-1338. Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in 21 1.7 6 Life. Journal of Cardiac Failure, 2021, 27, 435-444. The Arrhythmogenic Impact of Heart Failure With Preserved Ejection Fraction on Diabetics. American Journal of Cardiology, 2021, 141, 149-150. How Diabetes and Heart Failure Modulate Each Other and Condition Management. Canadian Journal of 23 1.7 10 Cardiology, 2021, 37, 595-608. Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. British Journal of General Practice, 1.4 2021, 71, e62-e70. Cardiorespiratory fitness in patients with type 2 diabetes: A missing piece of the puzzle. Heart Failure 25 3.9 12 Reviews, 2021, 26, 301-308. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 2021, 18, 400-423. 13.7 26 198 Impact of insulin resistance on subclinical left ventricular dysfunction in normal weight and 27 6.8 13 overweight/obese japanese subjects in a general community. Cardiovascular Diabetology, 2021, 20, 22. Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovascular 6.8 Diabetology, 2021, 20, 25. Heart Failure With Preserved Ejection Fraction. , 2021, , 201-222. 29 0 HFpEF: Should We Consider DiabeticÂPatients Separately?. Journal of the American College of Cardiology, 2021, 77, 420-422. Beyond the myocardium: Sodiumâ€glucose coâ€transporterâ€2 inhibitors in heart failure. Diabetes, Obesity $\mathbf{31}$ 4.4 0 and Metabolism, 2021, 23, 1215-1218. Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort. Cardiovascular Diabetology, 2021, 20, 48. 6.8 24 Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection 33 4.1 18 Fraction. JACC Basic To Translational Science, 2021, 6, 89-99. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052. Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection 35 1.7 1 fraction. Annals of Translational Medicine, 2021, 9, 523-523. CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia. Circulation 4.5 38 Research, 2021, 129, 98-113.

#	Article	IF	CITATIONS
37	Heart Failure And Diabetes: Perspective Of A Dangerous Association. Current Hypertension Reviews, 2021, 17, 85-93.	0.9	2
38	Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2022, 29, 1233-1243.	1.8	16
39	A Review of the Role of Type 2 Diabetes and SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction. Cardiology in Review, 2021, Publish Ahead of Print, .	1.4	1
40	SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine, 2021, 36, 100933.	7.1	67
41	In vivo reprogramming as a new approach to cardiac regenerative therapy. Seminars in Cell and Developmental Biology, 2022, 122, 21-27.	5.0	12
42	Relation of endothelial and cardiac autonomic function with left ventricle diastolic function in patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2022, 38, e3484.	4.0	6
43	A cross sectional study to compare cardiac structure and diastolic function in adolescents and young adults with youth-onset type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Study. Cardiovascular Diabetology, 2021, 20, 136.	6.8	9
44	Neutrophils proâ€inflammatory and antiâ€inflammatory cytokine release in patients with heart failure and reduced ejection fraction. ESC Heart Failure, 2021, 8, 3855-3864.	3.1	9
45	Chronic lowâ€grade inflammation in heart failure with preserved ejection fraction. Aging Cell, 2021, 20, e13453.	6.7	33
46	Association between cortisol and left ventricular diastolic dysfunction in patients with diabetes mellitus. Journal of Diabetes Investigation, 2022, 13, 344-350.	2.4	8
47	Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF. Frontiers in Cardiovascular Medicine, 2021, 8, 698117.	2.4	7
48	SIRT5-Related Desuccinylation Modification Contributes to Quercetin-Induced Protection against Heart Failure and High-Glucose-Prompted Cardiomyocytes Injured through Regulation of Mitochondrial Quality Surveillance. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-17.	4.0	43
49	Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus. , 0, , .		4
50	Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. Advanced Drug Delivery Reviews, 2021, 176, 113904.	13.7	49
51	Effect of diabetes mellitus on the development of left ventricular contractile dysfunction in women with heart failure and preserved ejection fraction. Cardiovascular Diabetology, 2021, 20, 185.	6.8	13
52	FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin αV/β5-AKT signaling and reduction of oxidative/nitrosative stress. Journal of Molecular and Cellular Cardiology, 2021, 160, 27-41.	1.9	41
53	General Treatment of Heart Failure With Preserved Ejection Fraction and Randomized Trials. , 2021, , 463-472.		0
54	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	3.9	3

#	ARTICLE Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future	IF 2.4	Citations
56	Perspectives. Journal of Cardiovascular Translational Research, 2021, 14, 63-74. CRP Induces NETosis in Heart Failure Patients with or without Diabetes. ImmunoHorizons, 2019, 3, 378-388.	1.8	28
57	Heart Failure with Preserved Ejection Fraction: the Major Unmet Need in Cardiology. Korean Circulation Journal, 2020, 50, 1051.	1.9	15
58	On the search for the right definition of heart failure with preserved ejection fraction. Cardiology Journal, 2020, 27, 449-468.	1.2	13
59	Intersection Between Diabetes and Heart Failure: Is SGLT2i the "One Stone for Two Birds―Approach?. Current Cardiology Reports, 2021, 23, 171.	2.9	2
60	Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 656536.	2.4	13
61	Research Progress of Heart Failure with Preserved Ejection Fraction. Advances in Clinical Medicine, 2021, 11, 4831-4840.	0.0	0
62	Lower Bâ€ŧype natriuretic peptide levels predict left ventricular concentric remodelling and insulin resistance. ESC Heart Failure, 2022, 9, 636-647.	3.1	6
63	Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: a systematic review and meta-analysis. Hellenic Journal of Cardiology, 2022, 64, 58-66.	1.0	7
64	Mitophagy Disequilibrium, a Prominent Pathological Mechanism in Metabolic Heart Diseases. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 4631-4640.	2.4	9
65	Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes. Biomolecules, 2022, 12, 176.	4.0	20
66	Transforming growth factor-Î ² in myocardial disease. Nature Reviews Cardiology, 2022, 19, 435-455.	13.7	87
67	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. Diabetes Therapy, 2022, 13, 241-250.	2.5	11
68	Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes. Current Atherosclerosis Reports, 2022, 24, 109-117.	4.8	4
69	Meta-analysis addressing the impact of cardiovascular-acting medication on peak oxygen uptake of patients with HFpEF. Heart Failure Reviews, 2022, 27, 609.	3.9	2
70	Diabetes-Induced Cellular Senescence and Senescence-Associated Secretory Phenotype Impair Cardiac Regeneration and Function Independently of Age. Diabetes, 2022, 71, 1081-1098.	0.6	30
71	Capillaries as a Therapeutic Target for Heart Failure. Journal of Atherosclerosis and Thrombosis, 2022, 29, 971-988.	2.0	4
72	Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity. Frontiers in Physiology, 2021, 12, 785879.	2.8	3

#	Article	IF	CITATIONS
73	Coronary microvascular dysfunction and findings of heart failure with preserved ejection fraction in patients with microvascular angina. Minerva Medica, 2022, , .	0.9	2
74	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	2.3	1
75	Global status and trends in heart failure with preserved ejection fraction over the period 2009-2020. Medicine (United States), 2022, 101, .	1.0	1
76	Serum-Induced Expression of Brain Natriuretic Peptide Contributes to Its Increase in Patients with HFpEF. International Journal of Molecular Sciences, 2022, 23, 2991.	4.1	1
77	Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer. Journal of the American Heart Association, 2022, 11, e023895.	3.7	1
79	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1016-1030.	1.7	5
80	Targeting the Metabolic-Inflammatory Circuit in Heart Failure With Preserved Ejection Fraction. Current Heart Failure Reports, 2022, 19, 63-74.	3.3	5
81	Association of Baseline and Longitudinal Changes in Frailty Burden and Risk of Heart Failure in Type 2 Diabetes—Findings from the Look AHEAD Trial. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 2489-2497.	3.6	9
82	Evaluating the adverse outcome of subtypes of heart failure with preserved ejection fraction defined by machine learning: A systematic review focused on defining high risk phenogroups EXCLI Journal, 2022, 21, 487-518.	0.7	3
83	Revelation of subclinical left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus using 2016 ASE/ EACVI guidelines. Caspian Journal of Internal Medicine, 2021, 12, 586-592.	0.2	3
84	Impact of Diabetic Retinopathy on Prognosis of Patients with Heart Failure with Preserved Ejection Fraction. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	2.6	0
85	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. Journal of Molecular Cell Biology, 2022, 14, .	3.3	16
86	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. Journal of Cardiovascular Development and Disease, 2022, 9, 149.	1.6	7
87	Relationship between adipose tissue distribution and arterial stiffness in HFpEF. Nutrition, 2022, 102, 111726.	2.4	5
89	Clinical Phenotypes of HeartÂFailure With Preserved Ejection Fraction to Select Preclinical Animal Models. JACC Basic To Translational Science, 2022, 7, 844-857.	4.1	11
90	Heart failure with normal LVEF in BIOSTAT-CHF. International Journal of Cardiology, 2022, 364, 85-90.	1.7	1
91	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35.	2.2	5
92	Effects of glycemic traits on left ventricular structure and function: a mendelian randomization study. Cardiovascular Diabetology, 2022, 21, .	6.8	6

#	Article	IF	CITATIONS
93	Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials. International Journal of Medical Sciences, 2022, 19, 1118-1121.	2.5	4
94	The future of heart failure with preserved ejection fraction. Herz, 2022, 47, 308-323.	1.1	12
95	What dietary interventions have been tested in heart failure with preserved ejection fraction? A systematic scoping review. European Journal of Cardiovascular Nursing, 2023, 22, 126-140.	0.9	3
96	Neutrophils and Circulating Inflammatory Biomarkers in Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2022, 178, 80-88.	1.6	1
97	The Diabetic Cardiorenal Nexus. International Journal of Molecular Sciences, 2022, 23, 7351.	4.1	6
98	Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovascular Research, 2023, 118, 3434-3450.	3.8	49
99	Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes. Journal of Pharmacology and Experimental Therapeutics, 2023, 384, 116-122.	2.5	42
100	The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure. Biomedicines, 2022, 10, 1751.	3.2	5
102	Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes. Diabetes Care, 2022, 45, 2999-3006.	8.6	9
103	Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?. Herz, 0, , .	1.1	1
104	Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Clucose Co-transporter-2 Inhibitors and Potential Mechanism. Journal of Cardiovascular Translational Research, 2023, 16, 327-340.	2.4	4
106	Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. Circulation, 2022, 146, 676-686.	1.6	46
107	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. , 0, Publish Ahead of Print, .		0
108	Epidemiology, Diagnosis, Pathophysiology, and Initial Approach to Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 397-413.	2.2	6
109	SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes. Circulation Research, 2022, 131, 926-943.	4.5	18
110	Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, the, 2022, 10, 869-881.	11.4	15
111	Oncometabolism: A Paradigm for the Metabolic Remodeling of the Failing Heart. International Journal of Molecular Sciences, 2022, 23, 13902.	4.1	2
112	Blocking MG53 ^{S255} Phosphorylation Protects Diabetic Heart From Ischemic Injury. Circulation Research, 2022, 131, 962-976.	4.5	8

		CITATION REPORT		
#	Article		IF	Citations
113	The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies.	, 2023, 14, 46.		9
115	The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus. Cardiovascular Diabetology, 2022, 21, .	with the	6.8	5
116	Microvascular Disease and the Pathogenesis of Heart Failure in Diabetes: A Tiny Piece of Puzzle. Diabetes Care, 2022, 45, 2817-2819.	the Tricky	8.6	3
117	Plasma metabolomic analysis reveals the therapeutic effects of Jiashen tablets on heart f Frontiers in Cardiovascular Medicine, 0, 9, .	ailure.	2.4	2
118	Prevalence and treatment of diabetes and pre-diabetes in a real-world heart failure popul single-centre cross-sectional study. Open Heart, 2022, 9, e002133.	ation: a	2.3	3
120	Evaluation of Microvascular Rarefaction in Vascular Cognitive Impairment and Heart Failu (CRUCIAL): Study Protocol for an Observational Study. Cerebrovascular Diseases Extra, 2	ure 2023, 13, 18-32.	1.5	2
121	Streptozotocin-Induced Type 1 and 2 Diabetes Mellitus Mouse Models Show Different Fu Cellular and Molecular Patterns of Diabetic Cardiomyopathy. International Journal of Mol Sciences, 2023, 24, 1132.	unctional, lecular	4.1	19
122	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Eje Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers Cardiovascular Medicine, 0, 9, .	ction in	2.4	11
123	Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database. International Journal of Cardiology, 2023, 378, 71-76.		1.7	0
124	SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A me of randomized controlled trials. Heart and Lung: Journal of Acute and Critical Care, 2023	eta-analysis , 59, 109-116.	1.6	8
125	The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Womer Diabetes Mellitus and Chronic Heart Failure. Biomedicines, 2023, 11, 457.	ו with Type 2	3.2	5
126	Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Prese Ejection Fraction. CJC Open, 2023, 5, 380-391.	erved	1.5	1
127	Diabetes Induces Cardiac Fibroblast Activation, Promoting a Matrixâ€Preserving Nonmyc Phenotype, Without Stimulating Pericyte to Fibroblast Conversion. Journal of the Americ Association, 2023, 12, .	ofibroblast an Heart	3.7	3
128	Association between triglyceride glucose index and subclinical left ventricular systolic dy in patients with type 2 diabetes. Lipids in Health and Disease, 2023, 22, .	sfunction	3.0	3
129	2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Pr Fraction. Journal of the American College of Cardiology, 2023, 81, 1835-1878.	eserved Ejection	2.8	74
130	Reappraising the role of chronic inflammatory burden in heart failure. Journal of Gene Me	dicine, 0, , .	2.8	0
131	Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with pre ejection fraction: an umbrella review of systematic reviews and meta-analyses. Frontiers Cardiovascular Medicine, 0, 10, .	eserved in	2.4	1
132	Patient phenotype profiling in heart failure with preserved ejection fraction to guide ther decision making. A scientific statement of the Heart Failure Association, the European He Association of the European Society of Cardiology, and the European Society of Hyperte European Journal of Heart Failure, 2023, 25, 936-955.	apeutic eart Rhythm nsion.	7.1	20

#	Article	IF	CITATIONS
133	WATCH-DM risk score predicts the prognosis of diabetic phenotype patients with heart failure and preserved ejection fraction. International Journal of Cardiology, 2023, 385, 34-40.	1.7	2
134	Disparities in Postdischarge Ambulatory Care Followâ€Up Among Medicaid Beneficiaries With Diabetes, Hospitalized for Heart Failure. Journal of the American Heart Association, 2023, 12, .	3.7	2
135	Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews. Heart Failure Reviews, 2023, 28, 1033-1051.	3.9	2
136	The double-hit protocol induces HFpEF and impairs myocardial ubiquitin-proteasome system performance in FVB/N mice. Frontiers in Physiology, 0, 14, .	2.8	0
138	Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes. Contemporary Diabetes, 2023, , 779-819.	0.0	0
139	Insulin resistance is associated with subclinical myocardial dysfunction and reduced functional capacity in heart failure with preserved ejection fraction. Journal of Cardiology, 2024, 83, 100-104.	1.9	1
140	Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes. Diabetology and Metabolic Syndrome, 2023, 15, .	2.7	1
142	Obesity in heart failure with preserved ejection fraction with and without diabetes: risk factor or innocent bystander?. European Journal of Preventive Cardiology, 0, , .	1.8	3
143	Perils and Pitfalls With Associations in HeartÂFailure, Particularly in HF-pEF. JACC Asia, 2023, 3, 622-624.	1.5	0
144	Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: From fundamental research to therapy. International Immunopharmacology, 2023, 123, 110747.	3.8	2
145	Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial. Cardiovascular Diabetology, 2023, 22, .	6.8	1
146	The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice. Cardiovascular Diabetology, 2023, 22, .	6.8	1
147	Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose. JCI Insight, 2023, 8, .	5.0	3
148	Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery. Acta Pharmacologica Sinica, 2024, 45, 23-35.	6.1	2
149	Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Development and Disease, 2023, 10, 310.	1.6	1
150	The immunology of heart failure with preserved ejection fraction. Clinical Science, 2023, 137, 1225-1247.	4.3	0
151	Myocardial deformation imaging by 2D speckle tracking echocardiography for assessment of diastolic dysfunction in murine cardiopathology. Scientific Reports, 2023, 13, .	3.3	1
152	Early repeat hospitalization for fluid overload in individuals with cardiovascular disease and risks: a retrospective cohort study. International Urology and Nephrology, 2024, 56, 1083-1091.	1.4	0

#	Article	IF	CITATIONS
153	Diabetes and associated cardiovascular complications: The role of microRNAs. Cardiology Plus, 0, , .	0.7	0
154	The effect of SGLT2 inhibitors on cardio-electrophysiological balance index in diabetic patients with preserved ejection heart failure. Archives of Current Medical Research, 2023, 4, 192-197.	0.1	Ο
155	Heart failure with preserved ejection fraction: New challenges and new hopes. Presse Medicale, 2024, 53, 104185.	1.9	1
156	Assessment of left atrioventricular coupling and left atrial function impairment in diabetes with and without hypertension using CMR feature tracking. Cardiovascular Diabetology, 2023, 22, .	6.8	0
157	Sex-specific differences in risk factors, comorbidities, diagnostic challenges, optimal management, and prognostic outcomes of heart failure with preserved ejection fraction: A comprehensive literature review. Heart Failure Reviews, 2024, 29, 235-256.	3.9	0
158	Treatment with recombinant Sirt1 rewires the cardiac lipidome and rescues diabetes-related metabolic cardiomyopathy. Cardiovascular Diabetology, 2023, 22, .	6.8	0
159	TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2024, 1870, 166979.	3.8	0
160	Recent advances in mechanistic studies of heart failure with preserved ejection fraction and its comorbidities—Role of <scp>microRNAs</scp> . European Journal of Clinical Investigation, 2024, 54, .	3.4	1
161	The Effects of Therapy for Iron Deficiency in Patients With Different Etiologies of Heart Failure and Concomitant Diseases. Kardiologiya, 2023, 63, 87-95.	0.7	0
162	The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment. Biomedicines, 2023, 11, 2928.	3.2	0
163	Obesity, heart failure with preserved ejection fraction, and the role of glucagonâ€like peptideâ€1 receptor agonists. ESC Heart Failure, 0, , .	3.1	0
164	Diabetes and risk of heart failure in people with and without cardiovascular disease: systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2024, 207, 111054.	2.8	0
165	Mortality and Hospitalization Rate of Heart Failure Patients with Preserved Ejection Fraction Treated with Dapagliflozin vs. Empagliflozin. , 2023, 1, 127-136.		0
166	Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target. Journal of Cardiovascular Development and Disease, 2024, 11, 12.	1.6	0
167	Circulating sphingolipids and relationship to cardiac remodelling before and following a low-energy diet in asymptomatic Type 2 Diabetes. BMC Cardiovascular Disorders, 2024, 24, .	1.7	0
168	Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach. International Journal of Molecular Sciences, 2024, 25, 794.	4.1	1
170	The two different profiles in heart failure with preserved ejection fraction and type 2 diabetes mellitus: ischemic and diabetic. Current Medical Research and Opinion, 2024, 40, 359-366.	1.9	0
171	The WATCH-DM risk score estimates clinical outcomes in type 2 diabetic patients with heart failure with preserved ejection fraction. Scientific Reports, 2024, 14, .	3.3	0

#	Article	IF	CITATIONS
172	Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study. BMC Cardiovascular Disorders, 2024, 24, .	1.7	2
173	Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart. Journal of Cellular Physiology, 2024, 239, .	4.1	0
174	Screening for heart failure in patients with diabetes mellitus in tertiary care – A SwissDiab study. Diabetes Research and Clinical Practice, 2024, 209, 111565.	2.8	0
175	The Impact of Diabetes on Haemodynamic and Cardiometabolic Responses in Heart Failure With Preserved Ejection Fraction. Heart Lung and Circulation, 2024, 33, 376-383.	0.4	0
176	Epidemiology of heart failure in diabetes: a disease in disguise. Diabetologia, 2024, 67, 574-601.	6.3	0
177	Inhibition of ferroptosis reverses heart failure with preserved ejection fraction in mice. Journal of Translational Medicine, 2024, 22, .	4.4	0
178	Elevated ITGA1 levels in type 2 diabetes: implications for cardiac function impairment. Diabetologia, 2024, 67, 850-863.	6.3	0
180	Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon. Journal of Clinical Medicine, 2024, 13, 1375.	2.4	0
181	Long-term outcomes prediction in diabetic heart failure with preserved ejection fraction by cardiac MRI. European Radiology, 0, , .	4.5	0